Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 17,843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Surgical Site Infections, Post Operative Complication
Interventions: 2% chlorhexidine gluconate cloths; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metabolic Syndrome
Interventions: exercise, Diagnostics, Inhaled CO2-mixed air; Behavioral · Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hidradenitis Suppurativa
Interventions: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more

Conditions: Complication of Surgical Procedure, Postoperative Infection
Interventions: CALYPSO, Standard Care; Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Delirium, Postoperative, Delirium in Old Age
Interventions: Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention, Control; Combination Product · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio

Conditions: Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases
Interventions: Cefoxitin, Piperacillin-tazobactam; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 29
States / cities: Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 24 more

Conditions: Complications, Pregnancy
Interventions: Betamethasone; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 15 more

Conditions: Scar Prevention, Scar Reduction
Interventions: Placebo, AZX100; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Pasadena, California • DeLand, Florida • Orlando, Florida + 2 more

Conditions: Major Depressive Disorder
Interventions: Placebo, RO4995819; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 43
States / cities: Phoenix, Arizona • Oakland, California • Redlands, California + 37 more

Conditions: Essential Tremor, Neuromodulation
Interventions: Focused Ultrasound Neuromodulation - Sham Control, Focused ultrasound neuromodulation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: AST-120, Celphere CP-305; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Financial Incentive, Retinal Care DR; Behavioral
Lead sponsor: Retinal Care Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Sickle Cell Disease
Interventions: Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: Morbid Obesity, Noninvasive Ventilation, Deep Sedation
Interventions: High flow nasal cannula, Nasal Cannula; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus Type 2
Interventions: RO4998452, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Mild Traumatic Brain Injury
Interventions: functional magnetic resonance imaging fMRI; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Irvine, California

Conditions: Stroke, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anterior Cruciate Ligament Injuries, Post-Traumatic Osteoarthritis of Knee, Bone Marrow Aspirate Concentrate, ACL Injury
Interventions: Concentrated Bone Marrow Aspirate Injection, Sham Incision, Revision Anterior Cruciate Ligament Reconstruction; Biological · Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Netupitant and Palonosetron, Palonosetron, Dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 28
States / cities: Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Pain, Fatigue, Sleep Disturbance, Cancer
Interventions: Cognitive-Behavioral Intervention, Attention Control; Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Rockford, Illinois • Janesville, Wisconsin • Madison, Wisconsin + 1 more

Conditions: Dry Eye
Interventions: Intravenous Immune Globulin (IVIG), Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infantile Hemangioma
Interventions: Propranolol three times a day, Propranolol twice a day, Timolol; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 18 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: GERD
Interventions: XP19986 CR, Placebo for XP19986 CR; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Stanford, California • Charleston, South Carolina • Tacoma, Washington

Search by objective public record fields.

2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

Exercise and Carotid Artery Function in Metabolic Syndrome

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

CALYPSO Pilot Study: Machine Learning Based Predictions of Surgical Complications

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Repeat Antenatal Steroids Trial

A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Ultrasound Neuromodulation in Essential Tremor

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

PROTECT2: Diabetes Care - Eye Exam

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients

Motor Learning in Stroke Patients and Healthy Volunteers

Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer

IVIG-eye Drops Treatment for Dry Eye Disease

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease